Brainstorm Cell Therapeutics I Financials
This page shows Brainstorm Cell Therapeutics I (BCLI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 23 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Brainstorm Cell Therapeutics I passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Brainstorm Cell Therapeutics I generates $0.78 in operating cash flow (-$9.1M OCF vs -$11.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Brainstorm Cell Therapeutics I's EBITDA was -$11.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 45.9% from the prior year.
Brainstorm Cell Therapeutics I reported -$11.6M in net income in fiscal year 2024. This represents an increase of 32.4% from the prior year.
Brainstorm Cell Therapeutics I earned $-2.31 per diluted share (EPS) in fiscal year 2024. This represents an increase of 61.5% from the prior year.
Brainstorm Cell Therapeutics I held $187K in cash against $0 in long-term debt as of fiscal year 2024.
Brainstorm Cell Therapeutics I had 6M shares outstanding in fiscal year 2024. This represents an increase of 52.3% from the prior year.
Brainstorm Cell Therapeutics I invested $4.7M in research and development in fiscal year 2024. This represents a decrease of 56.7% from the prior year.
BCLI Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $899K-14.0% | $1.0M | N/A | $3.3M | N/A | $3.8M | N/A | $3.6M |
| SG&A Expenses | $1.1M-42.7% | $2.0M | N/A | $2.7M | N/A | $3.1M | N/A | $1.7M |
| Operating Income | -$2.0M+32.8% | -$3.0M | N/A | -$6.0M | N/A | -$6.8M | N/A | -$5.3M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$2.1M+22.2% | -$2.7M | N/A | -$1.2M | N/A | -$6.9M | N/A | -$5.3M |
| EPS (Diluted) | $-0.19+62.7% | $-0.51 | N/A | $-0.45 | N/A | $-0.19 | N/A | $-0.15 |
BCLI Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.4M-24.7% | $1.8M-56.5% | $4.2M-25.9% | $5.7M-32.8% | $8.5M-36.2% | $13.3M-54.7% | $29.3M-15.2% | $34.5M |
| Current Assets | $508K+31.9% | $385K-79.7% | $1.9M+23.4% | $1.5M-50.5% | $3.1M-58.6% | $7.5M-67.8% | $23.3M-16.7% | $27.9M |
| Cash & Equivalents | $5K-97.3% | $187K-85.6% | $1.3M+6.4% | $1.2M+58.3% | $772K-81.4% | $4.1M-78.0% | $18.9M-26.6% | $25.7M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $9.1M-5.5% | $9.6M+5.8% | $9.1M+9.7% | $8.3M-27.9% | $11.5M-3.4% | $11.9M+19.4% | $9.9M+3.4% | $9.6M |
| Current Liabilities | $9.0M+0.5% | $9.0M+15.1% | $7.8M+23.4% | $6.3M-28.2% | $8.8M-1.7% | $8.9M+41.6% | $6.3M+8.1% | $5.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$7.7M+0.9% | -$7.8M-59.8% | -$4.9M-88.1% | -$2.6M+14.4% | -$3.0M-317.2% | $1.4M-92.8% | $19.3M-22.4% | $24.9M |
| Retained Earnings | -$234.5M-3.5% | -$226.6M-5.4% | -$215.0M-2.7% | -$209.4M-5.9% | -$197.8M-2.6% | -$192.8M-11.1% | -$173.5M-3.7% | -$167.4M |
BCLI Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.1M-5.2% | -$1.0M+68.1% | -$3.3M+48.7% | -$6.4M-37.9% | -$4.6M+4.2% | -$4.8M+11.9% | -$5.5M+14.7% | -$6.5M |
| Capital Expenditures | N/A | N/A | $0-100.0% | $18K | $0-100.0% | $1K-97.1% | $35K-85.2% | $237K |
| Free Cash Flow | N/A | N/A | -$3.3M+48.9% | -$6.4M-38.3% | -$4.6M+4.2% | -$4.9M+12.5% | -$5.5M+17.2% | -$6.7M |
| Investing Cash Flow | N/A | N/A | $196K+1733.3% | -$12K-101.2% | $1.0M+9536.4% | -$11K+99.2% | -$1.3M-176.5% | $1.7M |
| Financing Cash Flow | $313K-70.4% | $1.1M-68.4% | $3.4M-52.8% | $7.1M | N/A | N/A | -$34K+67.9% | -$106K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BCLI Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -152.6%-18.9pp | -133.7% | N/A | -21.6% | N/A | -51.7% | N/A | -15.4% |
| Current Ratio | 0.06+0.0 | 0.04-0.2 | 0.240.0 | 0.24-0.1 | 0.35-0.5 | 0.84-2.8 | 3.69-1.1 | 4.78 |
| Debt-to-Equity | -1.18+0.1 | -1.24+0.6 | -1.87+1.3 | -3.20+0.6 | -3.80-12.4 | 8.55+8.0 | 0.51+0.1 | 0.39 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$7.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.04), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
Is Brainstorm Cell Therapeutics I profitable?
No, Brainstorm Cell Therapeutics I (BCLI) reported a net income of -$11.6M in fiscal year 2024.
What is Brainstorm Cell Therapeutics I's earnings per share (EPS)?
Brainstorm Cell Therapeutics I (BCLI) reported diluted earnings per share of $-2.31 for fiscal year 2024. This represents a 61.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Brainstorm Cell Therapeutics I's EBITDA?
Brainstorm Cell Therapeutics I (BCLI) had EBITDA of -$11.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Brainstorm Cell Therapeutics I's operating cash flow?
Brainstorm Cell Therapeutics I (BCLI) generated -$9.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Brainstorm Cell Therapeutics I's total assets?
Brainstorm Cell Therapeutics I (BCLI) had $1.8M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Brainstorm Cell Therapeutics I spend on research and development?
Brainstorm Cell Therapeutics I (BCLI) invested $4.7M in research and development during fiscal year 2024.
How many shares does Brainstorm Cell Therapeutics I have outstanding?
Brainstorm Cell Therapeutics I (BCLI) had 6M shares outstanding as of fiscal year 2024.
What is Brainstorm Cell Therapeutics I's current ratio?
Brainstorm Cell Therapeutics I (BCLI) had a current ratio of 0.04 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Brainstorm Cell Therapeutics I's debt-to-equity ratio?
Brainstorm Cell Therapeutics I (BCLI) had a debt-to-equity ratio of -1.24 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Brainstorm Cell Therapeutics I's return on assets (ROA)?
Brainstorm Cell Therapeutics I (BCLI) had a return on assets of -634.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Brainstorm Cell Therapeutics I's cash runway?
Based on fiscal year 2024 data, Brainstorm Cell Therapeutics I (BCLI) had $187K in cash against an annual operating cash burn of $9.1M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Brainstorm Cell Therapeutics I's debt-to-equity ratio negative or unusual?
Brainstorm Cell Therapeutics I (BCLI) has negative shareholder equity of -$7.8M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Brainstorm Cell Therapeutics I's Piotroski F-Score?
Brainstorm Cell Therapeutics I (BCLI) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Brainstorm Cell Therapeutics I's earnings high quality?
Brainstorm Cell Therapeutics I (BCLI) has an earnings quality ratio of 0.78x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.